Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3693-8448
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.04 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.06. Galmed Pharmaceuticals had a negative net margin of 423.62% and a negative return on equity of 13.92%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
7 analysts have issued 12-month price targets for Galmed Pharmaceuticals' shares. Their predictions range from $20.00 to $59.00. On average, they expect Galmed Pharmaceuticals' share price to reach $35.75 in the next year. This suggests a possible upside of 322.6% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
What are Wall Street analysts saying about Galmed Pharmaceuticals stock?
Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We value ADMA via discounted cash flow (DCF)- based analysis, which models four principal lines of business (Nabi- HB, plasma reselling from ADMA’s own plasma center, BIVIGAM and RI-002). We apply a 10% discount rate and 30% effective tax rate, along with a 2.5% terminal growth rate." (3/14/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $59 12-month PT on Galmed Pharmaceuticals following earnings from 4Q18/2018. The company announced plans to have an end-of-Phase 2b meeting with the FDA during March, with the goal of initiating the Phase 3 ARMOR study in late-2Q19/early-3Q19. Minutes from this meeting and finalized Phase 3 trial design plans could be important data points in 2019. Additionally, Galmed will present a poster on Aramchol improvement in liver glucose homeostasis in NASH at EASL on 4/13 (link)." (3/13/2019)
- 3. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (2/28/2019)
Has Galmed Pharmaceuticals been receiving favorable news coverage?
Media coverage about GLMD stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Revance Therapeutics (RVNC), Vectura Group (VEGPF), Magenta Therapeutics (MGTA), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX), Intra-Cellular Therapies (ITCI), ZIOPHARM Oncology (ZIOP), TG Therapeutics (TGTX), Synthorx (THOR), DiaMedica Therapeutics (DMCAF), ChemoCentryx (CCXI), Aurinia Pharmaceuticals (AUPH), Viking Therapeutics (VKTX), Kura Oncology (KURA) and NuCana (NCNA).
What other stocks do shareholders of Galmed Pharmaceuticals own?
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
- Mr. Yohai Stenzler, CFO & Controller (Age 36)
- Mr. Guy Nehemya, VP of Operations (Age 34)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
- Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 36)
Who are Galmed Pharmaceuticals' major shareholders?
Galmed Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (5.25%), Ibex Investors LLC (3.14%), First Midwest Bank Trust Division (1.35%), UBS Oconnor LLC (0.67%), UBS Oconnor LLC (0.67%) and Raymond James & Associates (0.54%).
Which institutional investors are selling Galmed Pharmaceuticals stock?
GLMD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Menta Capital LLC, UBS Oconnor LLC, UBS Oconnor LLC and Nantahala Capital Management LLC.
Which institutional investors are buying Galmed Pharmaceuticals stock?
GLMD stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Ibex Investors LLC, Premier Asset Management LLC, Raymond James & Associates, ETF Managers Group LLC, BlackRock Inc. and Northern Trust Corp.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $8.46.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $177.83 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.
What is Galmed Pharmaceuticals' official website?
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
